scholarly journals SP733CHANGES IN BIOIMPEDANCE ANALYSIS MEASURES IN CHRONIC HEMODIALYSIS PATIENTS DURING ONE YEAR

2015 ◽  
Vol 30 (suppl_3) ◽  
pp. iii619-iii620
Author(s):  
Ruta Vaiciuniene ◽  
Irmante Stramaityte ◽  
Edita Ziginskiene ◽  
Vytautas Kuzminskis ◽  
Inga Arune Bumblyte
Keyword(s):  
Hemodialysis Patients ◽  
Chronic Hemodialysis ◽  
Bioimpedance Analysis ◽  
One Year

Stenosis at the area of Transposition – An Under-Recognized Complication of Transposed Brachiobasilic Fistulas

2007 ◽  
Vol 8 (4) ◽  
pp. 268-274 ◽  
Author(s):  
M.C. Beaulieu ◽  
C. Gabana ◽  
C. Rose ◽  
P.S. Macdonald ◽  
J. Clement ◽  
...  
Keyword(s):  
Hemodialysis Patients ◽  
Chronic Hemodialysis ◽  
High Rate ◽  
Secondary Patency ◽  
Basilic Vein ◽  
Av Fistula ◽  
Surgical Interventions ◽  
Secondary Patency Rate ◽  
One Year ◽  
The Impact

Background With an increased focus on native AV fistula creation in hemodialysis patients, a transposed brachiobasilic fistula (tBBF) is becoming an increasingly utilized option. This study describes the outcomes of tBBFs in a chronic hemodialysis population. In particular, we focus on the incidence and location of stenosis, and review the impact of angioplasty on these lesions. Methods A retrospective cohort study using all patients with a tBBF created between January 2001 and December 2004. Results Of the 543 fistulas created during the study period, 93 were tBBFs. The mean age of patients was 65 years, 56% were male and 55% were diabetic. Stenosis occurred in 54% (46/85) of fistulas; the location of stenosis in the majority (74%) was at or near the area of basilic vein transposition and 50% of fistulas with stenosis in this location required three or more angioplasties. Primary (unassisted) patency was 42% at one year in this cohort. Secondary patency was 68% at 1 year and 58% and 53% at 2 and 3 years respectively. Conclusion In a cohort of hemodialysis patients who received a tBBF, we describe a reasonable primary and secondary patency rate and a high rate of stenosis at the point of transposition of the basilic vein. Such stenosis usually requires multiple percutaneous or surgical interventions to ensure or reestablish conduit patency. Further study is required regarding the optimal surgical technique, monitoring, and treatment of stenosis of this fistula type including the utility of repeat angioplasty.

scholarly journals SP653WEIGHT LOSS IN CHRONIC HEMODIALYSIS PATIENTS: PREVALENCE, RELATION TO BODY COMPOSITION AND SURVIVAL DURING ONE YEAR

2018 ◽  
Vol 33 (suppl_1) ◽  
pp. i566-i566
Author(s):  
Irmante Stramaityte ◽  
Neda Kusleikaite-Pere ◽  
Ruta Vaiciuniene ◽  
Edita Ziginskiene ◽  
Vytautas Kuzminskis ◽  
...  
Keyword(s):  
Body Composition ◽  
Hemodialysis Patients ◽  
Chronic Hemodialysis ◽  
One Year

scholarly journals MO918INFECTIOUS COMPLICATIONS IN HEMODIALYSIS: INTERSET OF NEUTROPHIL TO LYMPHOCYTE AND PLATELETS TO LYMPHOCYTE RATIOS

2021 ◽  
Vol 36 (Supplement_1) ◽  
Author(s):  
Rania Lahouimel ◽  
Toumi Salma ◽  
Hanen Abid ◽  
Emna Kharrat ◽  
Amira Saai ◽  
...  
Keyword(s):  
Cross Sectional Study ◽  
Hemodialysis Patients ◽  
Infectious Complications ◽  
Chronic Hemodialysis ◽  
Cross Sectional ◽  
Positive Correlation ◽  
Literature Reviews ◽  
History Of ◽  
The Mean ◽  
One Year

Abstract Background and Aims Infectious complications represent the leading cause of death among the dialysis population, prompting early diagnosis and increased vigilance. Neutrophil-to-lymphocyte and platelets-to-lymphocyte ratios are newly emerging as more accessible and simple markers for the detection of the onset of infections. The objective of our study is to prove the value of these markers in the diagnosis of infections in hemodialysis patients. Method This is a cross-sectional study spread over one year including 85 chronic hemodialysis patients with duration of at least 6 months. patients with hemopathies, tumors, or with a history of hospitalization during the 3 months before the study were excluded. CRP was used as a biomarker of infections and N / L; P / L ratios were calculated to study the correlation between the two biomarkers. Based on the literature reviews, the threshold of the N / L ratio and the P / L ratio admitted for our stydy were respectively : > = 2.5 and > = 150. Results The mean age of our patients was 49 ± 19 years with a predominance of women (55%) .The average duration in hemodialysis was 67.2 months. An infectious complication was noted in 22% of our patients whose distribution was as follow: 4% as a pulmonary infection with 3 coronavirus cases, 6% a sepsis, one case of abscess of the nephrectomy compartment.The median value of the CRP was 37±10mg/l We found a positive correlation between the 2 ratios associated (RNL and RPL) and infection with (p = 0.03) . We noted throw this study that patients with both high ratios RPL> 150 and RNL> 2.5 have significantly elevated values of CRP. Conclusion N/L and P/L ratios are easy-to-calculate markers that are of great benefit to the hemodialysis population. We have shown through this study the existence of a positive correlation between the N/L and P/L ratios and the occurrence of infections in hemodialysis patients. We therefore encourage the use of this ratios to be included as markers to detect infections occurence.

Cost Avoidance and Clinical Benefits Derived from a Pharmacy-Managed Anemia Program

2000 ◽  
Vol 35 (2) ◽  
pp. 169-175 ◽  
Author(s):  
Robert A. Quercia ◽  
Ronald Abrahams ◽  
C. Michael White ◽  
John D'Avella ◽  
Mary Campbell
Keyword(s):  
Cost Savings ◽  
Cost Effective ◽  
Hemodialysis Patients ◽  
Cost Avoidance ◽  
Number Of Patients ◽  
Epoetin Alpha ◽  
Clinical Benefits ◽  
Unit Dose ◽  
One Year ◽  
Alpha Therapy

A pharmacy-managed anemia program included distribution and clinical components, with the goal of making epoetin alpha therapy for hemodialysis patients more cost-effective. The Pharmacy Department prepared epoetin alpha doses for patients in unit-dose syringes, utilizing and documenting vial overfill. Pharmacists dosed epoetin alpha and iron (oral and intravenous) per protocol for new and established patients. Baseline data were obtained in 1994, one year prior to implementation of the program, and were re-evaluated in 1995 and 1998. Cost avoidance from utilization of epoetin alpha vial overfill in 1995 and 1998 was $83,560 and $91,148 respectively. In 1995 and 1998, cost avoidance from pharmacy management of anemia was $191,159 and $203,985 respectively. The total cost avoidance from 1995 through 1998 was estimated at $1,018,638. The number of patients with hematocrits under 31% decreased from 32% in 1994 to 21% and 14% in 1995 and 1998 respectively. We conclude that a pharmacy-managed anemia program for hemodialysis patients results in significant cost savings and better achievement of target hematocrits.

Physical activity patterns in chronic hemodialysis patients: Comparison of dialysis and nondialysis days

2005 ◽  
Vol 15 (2) ◽  
pp. 217-224 ◽  
Author(s):  
Karen M. Majchrzak ◽  
Lara B. Pupim ◽  
Kong Chen ◽  
Cathi J. Martin ◽  
Sheila Gaffney ◽  
...  
Keyword(s):  
Physical Activity ◽  
Activity Patterns ◽  
Hemodialysis Patients ◽  
Chronic Hemodialysis ◽  
Physical Activity Patterns
Sign in / Sign up

Export Citation Format

Share Document